Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 2 | N022977 | — |
No reported signs/symptoms of adverse events.; second dose in the vaccination series on 10/07/2019 and the expiration date of VARIVAX was n022977 / 08/23/2019, post expiry date; Information has been received from Business Partner/CRO on 11-Feb-2025. This spontaneous report was received from a/an Other health professional and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 07-Oct-2019, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX REFRIGERATOR STABLE), (lot #N022977, expiration date: 23-Aug-2019) (2nd dose),. On 07-Oct-2019, the patient started therapy with sterile diluent (MERCK STERILE DILUENT), (indication, expiration date, and lot # were not reported). The patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX REFRIGERATOR STABLE), for the treatment of Prophylaxis. On 07-Oct-2019, the patient experienced second dose in the vaccination series on 10/07/2019 and the expiration date of VARIVAX was n022977 / 08/23/2019, post expiry date. On an unknown date, the patient experienced No reported signs/symptoms of adverse events.. At the reporting time, the outcome of second dose in the vaccination series on 10/07/2019 and the expiration date of VARIVAX was n022977 / 08/23/2019, post expiry date and No reported signs/symptoms of adverse events. was unknown. The action taken with sterile diluent and Varicella Virus Vaccine Live (Oka-Merck) was reported as not applicable.
Sterile diluent